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Abstract 
Emery Dreifuss muscular dystrophy (EDMD) is caused by mutations either in the gene 
encoding eme1in or in the gene encoding A-type lamins (lamins A and C). Several roles for 
emerin and A-type lamins have been proposed, including their involvement in nuclear 
structure, gene expression, cell cycle progression, and DNA replication. However, their 
functions are poorly understood and thus the mechanisms by which mutations cause 
different inherited diseases are not clear. In this project, the endogenous and exogenous 
distribution of emerin, and A- and B-type lamins in lymphoblasts and fibroblasts carrying 
mutations in emerin and A-type lamins have been investigated. For this purpose, antibodies 
against emei·in, and A- and B-type lamins as well as GFP-, and DsRed- tagged fusion 
proteins (GFP-emerin, GFP-lamin A, and DsRed-lamin C) were used. From the 
immunofluorescence microscopy results of lymphoblasts, it is suggested that the 
distribution of emerin and lamins is possibly affected in these cells in EDMD. However, in 
fibroblasts there was no evidence of structural abnormality for the proteins investigated. 
The effects of emerin and A-type lamins mutations on growth and progression of cells 
through the cell cycle have also been investigated in fibroblasts of EDMD patients, using 
flow cytometry. The results obtained here suggest that emerin and lamin mutations may 
cause a cell cycle arrest at the GO phase of the eye le. 
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Kntroduction 
Muscular dystrophies 
Muscular dystrophies are a large and heterogeneous group of inherited muscular 
disorders that are characterized by progressive weakness and wasting of muscles. Clinical 
and genetic findings from studies suggest that muscular dystrophies may be grouped into 
three broad categories: X-linked muscular dystrophies, autosomal dominant and autosomal 
recessive muscular dystrophies. In Table 1 some of the muscular dystrophies, their 
conesponding gene and its locus are listed. 
Duchenne/Becker and Emery-Dreifuss muscular dystrophy (EDMD) are the two 
major types of dystrophies, both characterized by progressive skeletal muscle wasting and 
cardiac abnom1alities (reviewed by Emery, 1989). 
Duchenne/Becker muscular dystrophy is the most prevalent form of muscle 
disorder. The gene responsible for this disorder and its product, dystrophin, were identified 
in late 1980's. Dystrophin is a large cytoskeletal/plasma membrane-associated protein 
expressed in muscle and brain. It localizes at the inner face of the sarcolemma and forms 
pm1 of a glycoprotein complex that links actin to the extracellular matrix. Studies of the 
genes encoding the proteins of the complex have provided evidence suggesting that the 
integrity of the dystrophin-glycoprotein complex is of great importance to maintaining the 
integrity of the membrane during contraction and relaxation of the muscle (reviewed by 
Betto et al., 1999). 
EDMD is quite distinct from all other forms of muscular dystrophy. The clinical 
features of the disorder have an onset in early childhood and a slow progression thereafter. 
EDMD is characterized by a triad of symptoms: (i) early contractures of the elbows, 
Achilles tendons and posterior neck, (ii) slow, progressive muscle weakening and wasting 
specifically localized in the humero-peroneal muscles, and (iii) cardiac conduction defects 
10 
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Table 1. Muscular dystrophies, their genes and loci. 
Muscular dystrophies Inheritance Gene locus Gene symbol Gene product 
Duchenne/Becker XR Xp21.2 DMD Dystrophin 
Emery-Dreifuss XR Xq28 XEMD Emerin 
Emery-Dreifuss AD lq21 ADEMD Lamin A/C 
Fascio-scapulo-humeral AD 4q35 FSHD 
Limb-girdle AD 5q22-q34 LGMDlA 
AD lq11-21 LGMDlB 
AD 3p25 LGMDlC Caveolin-3 
AR 15q15-q21 LGMD2A Calpain 3 
AR 2p13 LGMD2B Dysferlin 
AR 13ql2 LGMD2C y-sarcoglycan 
AR 17q12-q21 LGMD2D a-sarcoglycan 
AR 4ql2 LGMD2E ~-sarcogl ycan 
AR 5q33-q34 LGMD2F 8-sarcogl ycan 
AR 17q 11-q 12 LGMD2G 
AR 9q31-q34 LGMD2H 
Distal myopathy AR 2p12-14 MM Dysferlin 
(Miyoshi myopathy) 
Distal myopathy AD 14 MPDI 
Bethlem myopathy AD 21q22 COL6Al Collagen VI a 1 
COL6A2 Collagen VI a2 
AD 2q37 COL6A3 Collagen VI a3 
Epidermolysis bullosa AR 8q24-qter MD-EBS Plectin 
and muscular dystrophy 
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with conduction block. More than 40% of EDMD patients have a high risk of sudden death 
by heart block or develop a progressive cardiac failure. However, cardiac involvement in 
affected individuals is usually evident by the age of 30 and if diagnosed at an early stage, 
the cardiac defect can be cured by insertion of a pacemaker (Emery, 1989, 2000; Toniolo et 
al., 1998; Toniolo and Minetti, 1999). 
X-linked EDMD and Emerin 
Two fmms of EDMD have been described. An X-linked recessive fom1 and an 
autosomal dominant form, showing similar to identical clinical phenotypes (Morris and 
Manila!, 1999). The X-linked ED muscular dystrophy was first repm1ed by Dreifuss and 
Hogan as a benign fom1 of Duchenne muscular dystrophy. However it later became evident 
that this disease with the quite unusual symptoms was distinct fiom the Duchenne/Becker 
one and was given the term Emery-Dreifuss muscular dystrophy. 
The X-linked recessive fmm arises from mutations in the gene encoding emerin 
protein (Bione et el., 1995). The identification of the gene responsible for the disorder in 
1994 confirmed that the X-linked EDMD is indeed distinct from other muscular 
dystrophies (Bione et al., 1994). The gene locus for X-linked EDMD was mapped to the 
subchromosomal region Xq28 by linkage studies (Yates et al., 1993), and the 
cmTesponding gene designated as STA was identified by positional cloning (Bione et al., 
1994). The gene is very small, only 2,1 OObp in length, and consists of six exons with an 
mRNA of 1.3kb. This mRNA encodes a serine-rich protein of 254 amino acids (aa) with a 
Mr of 28,993, named emerin. 
Emerin Structure 
Structural analysis has shown that emerin is a type 11 integral protein of the inner 
nuclear membrane (INM), and belongs to a group of integral membrane proteins that 
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include lamina-associated proteins (LAP1, LAP2) and the lam in B receptor (Mon·is and 
Manila!, 1999). It has a shmi hydrophobic transmembrane region 11 residues from the 
carboxyl tenninus which contains the localization signal to the INM (Ostland et al., 1999). 
It also has a long hydrophilic N-terminal domain, which contains 22 putative 
phosphorylation sites for a range of kinases (Bione et al., 1996). The amino terminal 
domain, which extends into the nucleoplasm, has been shown to interact with non-
membrane insoluble elements, probably components of the nuclear lamina and chromatin 
(Manila! et al., 1996). 
Although emerin does not have an overall homology to any known proteins, aa 
sequences of both its N- and C-tenninal regions have some similarities to thymopoietins 
(TP). TP(3, one of the three isoforms of TP has been shown to be identical to LAP2 (HatTis 
et al., 1995). Moreover, emerin possesses two regions of homology to LAP2: a 39-residue 
region in its amino-terminal domain and the last 34 residues in the carboxyl-tenninal 
domain, are both 41% identical to similar! y positioned residues in LAP2 (Bione et al., 
1994, Furukawa et al., 1995). 
Gene Mutations 
Until now, 63 mutations in the gene encoding emerin have been reported 111 the 
Mutation Database available at OMIM (http://www.path.cam.ac.uk/emd/mutation.html). 
Mutations occur homogeneous throughout the gene and there is no evidence of mutational 
'hot spots'. The most common mutations reported are point mutations ( 49%) or small 
deletions (33%) I insetiions (1 0%). Moreover, some point mutations (14%) were found in 
the splice junctions. Most mutations (63%) introduce premature stop codons in the open 
reading frame (ORF), and therefore, no functional protein is being synthesized (Manila! et 
al., 1996; Yates et al., 1999). A relatively small percentage of mutations (8%) occur in the 
starting codon (A TG), probably preventing the initiation of translation. In addition, a small 
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but significant number of mutations on the gene have been repmted which result in 
modified emerin production (Yates et al., 1999). Interestingly, patients have been reported 
that carry point mutations or deletions/insertions in the last exon and in which emerin lacks 
the C-terminal part that contains the transmembrane domain of the protein. Some of these 
patients completely lack emerin, demonstrating thus the importance of the C-terminal 
domain for cellular localization and stability of the protein (Nagano et al., 1996; Manila! et 
al., 1998). Missense mutations and in-frame deletions described in patients also imply the 
importance of the molecular structure of emerin. In spite of the different mutations in the 
emerin gene, giving rise to a large number of different effects on the expression of the 
protein, the clinical features of all the EDMD patients are similar. 
Emerin Localization 
Although the clinical features associated with EDMD are specific and restricted, 
emerin expression is not restricted to the tissues which are clinically affected but is present 
in all other tissues studied so far (Manila! et al., 1996; Nagano et al., 1996; Manila! et al., 
1997; Mora et al., 1997). Immunological staining with antisera raised against different 
regions of emerin demonstrated that in normal cells the protein is localized at the nuclear 
rim in all tissues (Manila! et al., 1996; Nagano et al., 1996), in the intercalated discs of 
cardiac muscle cells (Cartegni et al., 1997), and in the endoplasmic reticulum (ER) of 
skeletal muscle cells (Fairley et al., 1999). Subcellular fractionation experiments also 
demonstrate that emerin localizes to the nuclear envelope in nonnal muscle, while they 
show that in EDMD muscle cells with nonsense mutations in the emerin gene, emerin is 
absent (Manila! et al., 1996, Nagano et al., 1996). In the same experiments, a small 
proportion of the protein was also found in the microsomal fraction which demonstrate 
association with cytoplasmic membranes and possibly transport to the nucleus through the 
ER (Manila! et al., 1996). Cmtegni et al., in 1997 reported the additional presence of emerin 
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at the intercalated discs in heart and cultured rat cardiomyocytes and suggested that cardiac 
conduction defects in EDMD might be explained by this additional localization of emerin. 
In relation to that, contractures and muscle wasting could also be accounted for if emerin 
was present at the myotendinous junctions as well, a structure related to the intercalated 
discs. However, later experiments showed that rabbit antisera can stain non specifically the 
intercalated discs and that both affinity-purified rabbit antibodies and monoclonal anti-
emerin antibodies stain the nuclear membrane but not the discs in the heart (Manilal et al., 
1999). 
Emerin Role and Function 
The role of emerin in the INM is not completely understood yet. A characteristic 
feature of emerin as was mentioned earlier is the high content of serine residues which can 
be phosphorylated/dephosphorylated by various protein kinases to create NE membrane 
bound/soluble emerin (Tsuchiya and Arahata, 1997). Studies have revealed that full size, 
nom1al emerin can occur in four different phosphorylated forms three of which appear to be 
associated with the cell cycle. The mutant forms of the protein on the other hand, can occur 
not only in four but in a large number of phosphorylated fonns (Ellis et al., 1998). These 
studies suggest that emerin's conect phosphorylation and thus localization at the INM is 
essential for its nonnal function. 
The functions of the integral membrane proteins 111 the INM in which emenn 
belongs are also not known yet. The experimental evidence available suggests that their 
function is closely related to the maintenance of the nuclear structure and architecture 
(Gerace and Foisner, 1994). Since skeletal and cardiac muscles and tissues surrounding 
joints are continuously subjected to vigorous movements, the mechanical stability of the 
nuclear membrane as well as the interactions with integral membrane proteins might be 
essential. 
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The similarity in molecular topology, ubiquitous expression and nuclear membrane 
localization as well as sequence homology between emerin and TP~/LAP2, suggests that 
the two proteins are functionally related. Nuclear envelope proteins have been shown to 
interact with lamins and chromosomes, and binding is reported to be modulated by mitotic 
phosphorylation (Foisner and Gerace, 1993). Mechanical connections between integrins, 
cytoskeletal filaments and cytoplasm that stabilize nuclear structure have also been 
demonstrated (Maniotis et al., 1997). Finally, emerin is found at intranuclear sites where it 
colocalizes with the nuclear lamins and binds strongly to several yet unidentified insoluble 
matrix components (Ellis et al., 1998; Manila! et al., 1998; Squarzoni et al., 1998). 
Three out of the four of emerin's different phosphorylated forms appear to be 
associated with the cell cycle. Data suggests that emerin may be involved in disassembly 
and reformation of the nuclear membrane during mitosis, as well as in maintenance of the 
nuclear membrane-chromatin organization structure during interphase. However, the 
viability of cells without emerin shows that it is not essential. More specifically, during 
mitosis emerin becomes dispersed tlu·oughout the cell, no longer colocalizing with the 
lamins. After mitosis and during the reassembly of the nuclei, a number of events take 
place such as targeting of the nuclear membrane to chromosomes, membrane fusion, 
nuclear pore complex (NPC) formation, lamina assembly and cluomatin decondensation. 
LAPs and LBR are shown to be involved in the targeting of the nuclear membrane to 
chromosomes. Although their exact role is not specified, at late anaphase when the 
cluomosomes are first enveloped with membranes, these proteins are traced at the 
chromosome surfaces at high concentrations (Ellenberg et al., 1997). 
Experiments conducted on the basis of the above revealed that emetin is focally 
accumulated in the nuclear membranes of late telophase cells participating in the 
reconstitution of membranes around the daughter nuclei. Emerin eo-localizes with Lamin 
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A!C, and is concentrated in some areas of the mitotic spindle and in the mid-body of 
mitotic cells (Manila! et al., 1998a; Dabauvalle et al., 1999). Tllis indicates that emetin is 
involved in cell cycle dependant events and in the reorganization of the nuclear envelope at 
the end of mitosis. The phosphorylation of emerin may be involved in controlling these 
events. 
Although the function of emerin is still unknown, the clinical, physiological and 
pathological changes are certainly caused by the deficiency of the protein in X-EDMD, and 
presumably by emerin-interacting molecule(s) in AD-EDMD. Possible functions of emerin 
are listed in Table 2. 
AD-lEDMD and Lamins 
The rarer form of EDMD, autosomal dominant EDMD (AD-EDMD) has been 
described recently. The gene responsible for this fmn1 of the disorder has been identified at 
lq21.3 (Bonne et al., 1999). It (LMNA) encodes two components of the nuclear lamina, 
lamins A and C of about 60-75kDa size, by alternatively splicing (Fisher et al., 1986; Lin 
and Woman, 1993; Bonne et al., 1999). 
Lamin !11utations 
Mutations 111 the LMNA gene in AD-EDMD can not be detected by 
immunohistochemistry (Bonne et al., 1999; Toniolo and Minetti, 1999), and diagnosis 
depends on mutation analysis facilitated by oligonucleotide microassay techniques (Hacia 
and Collins, 1999). One large AD-EDMD family has a mutation that produces a very early 
stop codon and thus a truncated lamin A/C composed of only the five amino-te1minal 
amino acids (Bonne et al., 1999). Missense mutations in the head and in the tail domains 
resulting in amino acid changes in highly conserved residues were found in additional 
families. Inununostaining of nuclei from AD-EDMD demonstrated that both emerin and 
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'fable 2. Possible functions of emerin 
1. Mechanical stability of the nuclear membrane and interaction with integral membrane 
proteins 
2. Regeneration of muscle fiber 
3. Regulation of gene expression and chromosome organization 
4. In heart, emerin localization to desmosomes and fasciae adherents could account for 
the characteristic conduction defects 
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Iamin A/C are present in these nuclei (Toniolo and Minetti, 1999). This suggests that AD-
EDMD is caused by haploinsufficiency for lamin A/C. Interestingly, another type of 
muscular dystrophy, the autosomal dominant form of limb-girdle muscular dystrophy with 
cardiac involvement, may be allelic with and therefore a variant of AD-EDMD (Van der 
Kooi et al., 1997). Furthermore, missense mutations in the rod domain in the LMNA gene 
result in dilated cardiomyopathy with conduction defects but no skeletal myopathy (Fatkin 
et al., 1999). Finally, LMNA mutations have been identified as the cause of Dunnigan-type 
familiar partial lipodystrophy associated with diabetes and coronary artery disease (Cao and 
Hegele, 2000). 
The properties of the mutant lamins that cause muscular dystrophy, lipodystrophy 
and dilated cardiomyopathy are not known. In a study conducted recently (Ostlund et al., 
200 I), fifteen mutant fonns of lamin A found in patients affected by the above diseases 
were investigated by transfections in C2C12 myoblasts. In four of these mutants 
immunofluorescence microscopy revealed decreased nuclear rim staining and formation of 
intranuclear foci. The distribution of endogenous lamin A/C, lamin B 1 and B2 was also 
affected in these four mutants resulting in accumulation of the proteins inside the foci. In 
addition, in three of these mutants emerin was lost from the nuclear envelope. The results 
suggest that some but not all the mutations occmTing in lamin A can disrupt the 
endogenous lamina and alter emerin localization. 
In agreement to that, it has been reported that some point mutations in lamin A/C 
gene that cause dilated cardiomyopathy and AD-EDMD modify the assembly properties of 
lamin A and lamin C and cause pm1ial mislocalization of emerin in HeLa cells. Moreover, 
these mutations also cause significant changes in the molecular organization of the nuclear 
periphery (Rahmjo et al., 2001). On the other hand, it has also been shown that R482Q and 
R482W mutations in lamin A do not involve loss of ability to fom1 a nuclear lamina or to 
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interact with emerin (Holt et al., 2001; Rahatjo et al., 2001). Interestingly, in another study 
involving these two mutations (Vigouroux et al., 200 I), a subpopulation of cells carrying 
these mutations showed nuclear envelope herniations lacking B-type lamins, NPCs, Lap2f3 
and chromatin. Fmihennore, abnonnal blebbing nuclei with a disorganized peripheral 
meshwork containing A-type lamins, emerin, and A-type lamin binding proteins were also 
observed, while the nuclear envelope was reported to have become more fragile. 
Lamin Structure 
Analysis of cDNA sequences that encode nuclear lamins has shown that lamins are 
closely related to the endoplasmic intermediate filament (IF) multi-gene protein family 
(Fisher et al., 1986), and are therefore classified as type V intermediate filaments (Quinlan 
et al., 1995). Structurally, IF proteins have a primary sequence consisting of a highly 
conserved central a-helical "rod" domain flanked by less conserved globular "head" and 
"tail" domains (Heins and Aebi, 1994). The rod domain in vetiebrate endoplasmic IF 
proteins is in most cases 310 aa in length, although some IF proteins can possess slightly 
smaller or larger rod domains (Hess et al., 1998; Wallace et al., 1998). The rod domain can 
be divided into three or four a-helical segments, coil 1 a, coil I b, coil 2a, and coil 2b, which 
are separated by non-a-helical linker sequences. Figure 1 shows a schematic representation 
of somatic cell lamins. 
In nuclear lamins the rod domain is 352 aa long, i.e. 42 aa longer than other IF 
proteins. The extra residues consist of six heptad repeats with a-helical properties located 
in coil 1 b (Weber et al., 1989a). It is interesting to note that invertebrate IF proteins also 
contain this 42 aa insert, implying thus that they are the precursor of lamins and that 
cytoplasmic IF proteins have evolved from lamins by the loss of that 42 aa inseti (Way et 
al., 1992). 
20 
------ - -- ---
Another difference between nuclear lamins and cytoplasmic IF proteins is that the former 
have a nuclear localization signal (NLS) in their tail domains adjacent to the a-helical rod 
domain (the exact position of the NLS within the tail domain varies between different 
lamins), and a COOH-terminal sequence motif CaaX (C, cysteine; a, any aliphatic amino 
acid; X. any amino acid) (Moir et al., 1995). 
The NLS facilitates the transport of the lamins to the nucleus and is homologous to 
the prototype NLS of the simian virus 40 large T antigen. The CaaX motif is required for 
famesylation of the C-terrninal cysteine that eventually leads to proteolytic cleavage of the 
C-terminal aaX residues and carboxy-methylation of the cysteine residue (reviewed within 
Vaughan et al., 2000b ). The CaaX modifications and more specifically the added 
hydrophobic phenyl moiety is thought to be impor1ant for the targeting and anchorage of 
lamins to the nuclear membrane (Yorburger et al., 1989). 
A-type and B-type Lamins 
The nuclear envelope (NE) creates a compartment within the interphase cell in 
which DNA replication, transcription and RNA processing are regulated independently of 
translation. It consists of 4 main structures; the inner nuclear membrane (INM) and the 
outer nuclear membrane (ONM), the nuclear pore complexes (NPCs) and the nuclear 
lamina (Hutchison et al., 1994). Lamins are the major component of the nuclear lamina and 
in addition they also fom1 intra-nuclear structures, as well as trans-nuclear tube-like 
structures (Bridges et al., 1993; Moir et al., 1994; Fricker et al., 1997). Two main types of 
lamins are known in manunals; A-type and B-type. A-type lamins, laminA, C, and A~10, 
are the alternatively spliced products of the same gene, Lamin A/C (Fisher et al., 1986; Lin 
and Worman, 1993; Furakuwa et al., 1994; Machiels et al., 1996). B-type lamins on the 
other hand which include B I, 82 and 83 lamins, are encoded by distinct genes (Pollard et 
al., 1990; Biamonti et al., 1992). 
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Fig.l. Schematic representation of somatic cell lamins. Rectangles represent a-helical 
coiled-coil domains. The shaded area in coil 1 b illustrates the position of the heptad repeat. 
Lamin Bi 
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CaaX 
LaminB2 
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Cytoplasmic IF 
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A-type and B-type lamins differ in several respects including their post-translational 
processing, behaviour at mitosis, and expression dming differentiation (Gerace and Blobel, 
1980; Famswmth et al., 1989). More specifically, 8-type lamins remain fam1esylated 
throughout their lifetime, while A-type lamins are processed fmther. The C-terminal 15 
residues of lamin A including the phenyl tail are removed by proteolytic cleavage to yield 
mature lamin A (Sasseville and Raymond, 1995). The retention of CaaX modifications 
confers different biochemical properties onto lamins. 
The different post-translational processing of A- and 8-type lamins may provide an 
explanation for their different behaviour at mitosis when nuclear and some cytoplasmic IFs 
are disassembled as a result of phosphorylation (Foisner, 1997). More specifically, during 
mitosis, the NE together with the lamina is disassembled and reassembled. Data from in 
vivo and in vitro assays suggest that the mitotic CDC2 kinase, protein kinase C (PKC), and 
cyclic-AMP-dependent kinase (PKA) phosphorylation sites are impmtant in lamin 
assembly as well as disassembly (Moir et al., 1995). The disassembly of the lamina is 
thought to take place by the dissociation from the NE of A-type lamins followed by B-tyPe 
lamins (Georgatos et al., 1997). Cdk1 complexed to cyclin B seem to be the main kinases 
responsible for lamin filament depolymerisation (reviewed in Moir et al., 1995). 
Phosphorylation sites for Cdk1 are located within the C-terminal domains of both types of 
lamins and more particularly at the end of coil 2, as well as within the N-tenninal domain, 
adjacent to coil 1 a of the rod domain. After disassembly of the NE and during mitosis, 
lamin A and lamin C probably form dimers and/or tetramers and remain 'soluble'. In 
contrast, B-type lamins generally remain most of the time attached to nuclear membrane 
vesicles (Gerace and Blobel, 1980). 
Protein phosphatases have been implicated in lamina assembly (Mmvhy et al., 
1995). In addition, phosphorylation by PKC at sites adjacent to the NLS can influence the 
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amount of lamins entering the nucleus, and therefore the availability of lamina's 'building 
blocks' (Hennekes et al., 1993). In contrast, PKA facilitates the incorporation of new lamin 
subunits into the lamina during nuclear growth (Peter et al., 1990). Finally, 
dephosphorylation by PP la at CDKl sites can influence the initial rate of lamin filament at 
telophase (Thompson et al., 1997). 
B-type lamins are ubiquitous components of all cells. They are present in all 
embryonic and nucleated somatic cells, although different cells may express different B-
type lamins (Furukawa and Hotta, 1993). In mammalian somatic cells the most conunon B-
type lamins present are lamins B 1 and 82 (Broers et al., 1997). A-type lamins on the other 
hand seem to be related to differentiation. They are present only in differentiated cells and 
tissues (Rober et al., 1989, 1990), and are observed in embryos at the time of 
differentiation. 
Lamin Role and Functions 
The functions of the nuclear lamins still remain unknown. It has been speculated 
however that they are involved in transcription regulation, chromatin organization, cell 
cycle progression and terminal differentiation. 
Evidence from a number of laboratories suggests that lamins are required for DNA 
replication. Investigation of the involvement of lamins in DNA synthesis has made use of 
deletion mutants of Xenopus lamin B 1 (Ell is et al., 1997) and human lamin A (Spann et al., 
1997) on nuclei assembled in Xenopus egg extracts. Results from these investigations 
concluded that both lamin mutants which lack the N-terminal globular head domain leading 
to the creation of dominant negative proteins, are capable of preventing lamina assembly, 
disrupting a prefonned lamina at S-phase nuclei and inhibiting DNA synthesis. In the case 
of lamin A mutant, the organization of some replication fork proteins was disrupted. The 
replication factor complex (RFC) and the proliferating cell nuclear antigen (PCNA) under 
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such conditions were found within intranuclear aggregates, eo-localizing with the 
endogenous lamin B3 sequestered by the headless lamin A. This data is consistent with the 
observation that B-type lamins colocalize with centres of DNA replication in cultured 
mammalian cells during mid to late S-phase (Moir et al., 1994; Izumi et al., 2000). This 
data suggests that B-type lamins may function as a scaffold on which the DNA replication 
complexes are formed. The Xenopus minichromosome maintenance complex factor 3 
(XMCM3), the Xenopus origin replication complex factor 2 (XORC2) and the DNA 
polymerase a however which are involved in the initiation of DNA synthesis, appeared to 
be unaffected. These observations imply that a properly assembled nuclear lamina is 
essential for the elongation phase of replication but not for the assembly of pre-replication 
complexes (Spann et al., 1997; Moir et al., 2000). In contrast to that, in another similar set 
of experiments involving lamin Bl mutants replication (elongation) was not blocked once 
sites of replication were established, although the lamina was disrupted (Ellis et al., 1997). 
These results suggest that lamina assembly is required to establish replication centres but is 
not essential for their maintenance and function. 
Other studies suggest that nuclear lamins play a more indirect role in DNA 
replication. After an ultrastructural study of sperm pronuclear assembly Zhang and eo-
workers in 1996 suggested that the nuclear matrix consists of two filamentous structures; 
lam in filaments that contain lamin B3, and core filaments of the intemal nuclear matrix that 
do not contain lamin 83 (Zhang et al., 1996). Furthennore, it was also suggested that the 
nmmal assembly of the nuclear matrix filaments and thus the nuclear matrix depends on 
conect assembly of the lamina although lamin B3 is not present in the core filaments. 
Because the nuclear matrix may support DNA replication centres, nuclear lamina assembly 
is required. In another study, a nuclear-free system in which DNA replication was initiated 
on chromosomal DNA added to concentrated nuclear extracts activated by cyclin E/Cdk2 
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was developed (Waiter et al., 1998). ln this case it was thought that the high concentration 
of replication factors in the nucleoplasmic extract overcomes the need of a NE and lamina. 
lt is therefore implied that the role of lamina in DNA replication is indirect and that its 
function involves efficient nuclear transport and concentration of the replication factors 
inside the nucleus. 
In agreement with the above are experiments in which the depletion of a nuclear 
pore complex protein or the addition of a nuclear transport inhibitor blocks replication 
(Powers et al., 1995; Waiter et al., 1998). Initiation of DNA replication in in vitro 
assembled nuclei has also been repotted to be size dependent (Hutchison et al., 1994), and 
lamin deficient nuclei are shown to anest for nuclear growth at a size smaller than that 
required for initiation (Ellis et al., 1997). 
The biochenlical prope1ties of the lamina and its association with the inner face of 
the nuclear membrane and the pores suggests that the lamina provides structural support for 
the NE (Moir et al., 1995). Nuclei assembled in vitro under lamin depleted conditions are 
fragile and easily broken (Moir et al., 1995). Perhaps the most convincing example 
demonstrating the importance of lamins for the nuclear structure is that of a mouse model 
for EDMD created by functional knockout of the lamin A/C gene (Sullivan et al., 1999). 
Lamin A/C null mice show no difference from normal mice at birth. However, after 3-4 
weeks they develop severe muscle wasting and contractures similar to that of EDMD, while 
they die after 8 weeks of bi1th. In cells lacking lamin A/C nuclei are reported to be 
misshapen while there is a severe ultrastructural damage. Furthermore, nuclei appear to 
have herniations where the envelope pulls away tl·om the chromatin, at which sites lamin 
82, LAP2 and pore complexes are disrupted. 
The first genetic evidence for the role of lamins in NE organization was provided by 
Lenz-Bohme et al., 1997. In Drosophila melanogaster two lamin genes are known coding 
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for lamins DmO and C which have some similarities to vetiebrate B-type and A-type 
lamins respectively (reviewed in Stumman et al., 1998). Inse11ional mutation in the DmO 
lamin gene ( <20% of lamin expression) results in a severe mutant phenotype with defective 
NE (abnormalities in the initial assembly of the NE and NPC distribution) and reduced 
viability ( Lenz- Bohme et al., 1997). Subsequent studies reported that flies homozygous for 
the lamin DmO gene mutations have aberrant nuclear structure and die after 9 to 14 hours 
of development, a time at which the maternal larnin DmO is diluted (Hare! et al., 1998). 
These results suggest that the main function of lamins is in stabilizing the NE. 
Recent studies have showed that the lamins are also impm1ant in NE assembly. NE 
assembly includes the targeting and f-usion of membrane vesicles to the surfaces of 
decondensing chromosomes, the assembly of NPCs, and the repolymerisation of the 
lamina. Studies demonstrate that lamins have an impm1ant role in targeting nuclear vesicles 
to chromatin after mitosis (Gant and Wilson, 1997). In one such study lamins B2 and B3 in 
Xenopus were functionally depleted from egg extracts by the use of antibodies and that 
inhibited nuclear membrane assembly (Dabauvalle et al., 1991 ). Similarly, in Drosophila 
embryo cell-free system it was shown that antibody depletion of lamin Dm1 blocked 
binding of NE vesicles to chromatin while addition of purified interphase lamin Dm1 and 
Dm2 isoforms or undepleted cytosol restored the binding (Ulitzur et al., 1992, 1997). These 
results however are contradicted by a series of other experiments. For instance, in sea 
urchin egg extracts, depletion of lamin B did not seem to have any impact on the initial 
stages of NE assembly, while depletion of lamin B receptor (LBR) inhibited membrane 
vesicles from binding to chromosomes (Collas et al., 1996). In Xenopus egg extracts, 
physical and functional depletion of lamin 83 did not block NE assembly either (Newport 
et al., 1990; Meier et al., 1991 ). Finally, physical depletion of B-type lamins in turkey 
erythrocytes extracts had a minor effect on the cluomosome-membrane vesicles binding 
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whereas again physical depletion of LBR completely inhibited binding (Pyrpasopoulou et 
al., 1996). 
Lamina flexibility is required for growth of the NE and for nuclear volume increase 
during the cell cycle while it also influences nuclear shape. Progression into S-phase 
depends on the acquisition of a minimal nuclear volume (Yang et al., 1997b ). Experimental 
data suggests that spen11-specific lamin B3 may play an important role in the organization 
of the meiotic cell's nuclear architecture since its expression results in the fom1ation of 
hook-shaped nuclei (Furukawa and Hotta, 1993; Furukawa et al., 1994). In addition, 
although inununodepletion of soluble lamin B3 (>95% of total lamin B3 content) in 
Xenopus egg extracts does not prevent NE assembly, the nuclei formed are significantly 
smaller and more fragile than normal ones (Newport et al., L 990; Jenkins et al., 1993). 
Similar results were also obtained after addition of dominant negative lam in mutant 
proteins which prevent lamina filament assembly to Xenopus egg extracts (Spaun et al., 
1996; Ellis et al., 1997). 
In vivo, lamin filaments are closely associated with chromatin fibers (Belmont et 
al., 1993) and in vitro they are shown to bind interphase chromatin (Ulitzur et al., 1997; 
Goldberg et al., 1999a), mitotic chromosomes (Glass et al., 1993) or specific DNA 
sequences (Zhao et al., 1996). The binding site of vertebrate lamins to chromatin is 
localized at the tail domain of the proteins and it has been shown to be displaced with the 
core histones H2A and H2B (Goldberg et al., 1999a). As was mentioned above, the 
expression of A-type lamins appears to be linked to differentiation. What is more, 
pluripotent cells treated so as to induce differentiation can be induced to express A-type 
lamins (Lebel et al., 1987) and in some cases, ectopic expression of lamin A has been 
shown to promote differentiation (Lourim and Lin, 1992). This has lead to the suggestion 
that A-type lamins may be involved in differential gene expression either by anchoring 
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chromatin to the NE or by sequestering inhibitors (Nigg, 1989). Consistent with this 
suggestion is the observation that lamin A has a higher atlinity for chromatin binding than 
B-type lamins (Hoger et al., 1991 ), and that A-type lamins also bind the negative growth 
regulator p 11 oRB (Ozaki et al., 1994). The effect of lamins on chromatin organization is 
also demonstrated in the experiments with lamin A/C null mice where the heterochromatin 
layer underlying the NE is either thin or absent. That suggests that lamin A/C null nuclei 
have difficulty attaching heterochromatin to the envelope or stabilizing its structure. 
Lamin Interactions 
Further understanding of the role of the lamins and lamina can be achieved through 
investigations of lamin binding partners. There are strong experimental evidence which 
show that the nuclear lamina and the INM associate through interactions between several 
integral nuclear membrane proteins (LBR, LAPI and 2), and lamins. LBR has an N-
tem1inal nucleoplasmic domain and a C-terminal region with 8 transmembrane domains. 
The nucleoplasmic domain of the receptor interacts with the B-type lamins (Worman et al., 
!998), with HP l (Human chromatin associate protein), and with chromatin in vitro (Ye et 
al., 1997). LAP1s (Lap1a, LAPI~, and LAP1y) interact with both A- and B-type lamins 
(Ye and Worman, 1994). LAP2s (LAP2a, ~' and y) on the other hand associate only with 
lamin B 1 as well as with chromatin in vitro (Foisner and Gerace, 1993; reviewed in 
Vaughan et al., 2000b). An exception to that is LAP2a protein which has been shown to 
also interact with laminA (Dechat et al., 2000). 
Lately it has been suggested that a complex similar to LAP2-lamin B 1 which may 
be related in function to it, is fonned between emerin and lamin A (Manila! et al., 1999; 
Monis and Manila], 1999). In support of the above, experiments have shown that the 
distribution of emerin in different cell types is similar to that of lamin A and difTerent from 
that of lamin B 1 and B2 (Manila! et al., 1999). In addition to that, it has also been found 
29 
that lamin A binds directly to the Tsuchiya-Ostlund sequence (Ostlund et al., 1999; 
Tsuchiya et al., 1999) of emerin (Clements et al, 2000). 
[nteractions between these proteins are regulated by phoshphorylation/dephosphorylation 
processes. LAP2, LBR and possibly LAP1 are shown to interact with chromatin during 
early anaphase and are therefore believed to be involved in the nuclear lamina assembly 
and chromatin decondensation (reviewed in Vaughan et al., 2000b ). In addition to that, 
LAP2[3, LBR and B-type lamin are probably involved in nuclear growth during interphase 
(Yang et al, 1997a and 1997b; reviewed in Vaughan et al, 2000b). Finally, B-type lamins 
colocalize with DNA replication centers in mid S-phase (Moir et al., 1994), which suggests 
that they are indirectly involved in DNA replication processes (Ellis et al., 1997; reviewed 
in Vaughan et al, 2000b ). 
Absence of or mutations in emerin or lamin A/C, have been shown to give rise to 
the EDMD syndrome with most affected tissues being the cardiac and skeletal muscle. The 
most probable explanation that has been proposed for this is that these proteins are pm1 of a 
nucleoskeletal network which maintains the NE integrity and protect it from mechanical 
stresses (Tsuchiya et al., 1999). Skeletal and cardiac muscles, in contrast to all the other cell 
types, are continuously subjected to mechanical stresses and that makes the effects of the 
absence/mutations of emerin, and lamins A and C, more severe in these tissues. 
An understanding of the lamina and emerin structure, function and interactions with 
the INM proteins is essential for fm1her understanding of the mechanisms underlying the 
EDMD syndrome, as well as other lamin associated diseases. 
In the expe1iments conducted in tllis project the following were investigated: 
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a) the way in which mutations of lamins/emerin affect the fragility of the nuclear 
envelope of cells by looking at the distribution of other lamins/emerin in these cells 
and comparing it with control cell lines, and 
b) whether or not lamins/emerin are involved in cell cycle control and growth of cells 
by investigating the distlibution of cells in the different phases of the cell cycle, 
both in nonnal and in lamin/emerin-mutated cell lines. 
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Chapter l. Lymphoblasts and fibroblasts as tools for diagnostic tests 
Introduction 
Emerin and lamins are present in many different cell types. However, the clinical 
characteristics of patients with X-linked and AD-EDMD are specific and restricted (cardiac 
conduction defects, early contractures at the neck, ankles and elbows, and slowly-
progressive wasting of certain specific muscles), with the cardiac and skeletal muscle being 
particularly sensitive to lack of emerin and lamin A/C (Emery, 2000). 
Staining of emerin and lamins with antibodies, as well as subcellular fractionation 
experiments have shown that these proteins are present in most tissues of the body and are 
localized mainly at the INM and lamina respectively in normal muscle cells and other 
tissues. Over-expressed recombinant emerin has also been reported to be present in small 
amounts in the cytoplasm and the plasma membrane of cultured cells (Ostlund et al., 1999), 
but there is no evidence as yet that it functions outside the nucleus under nom1al 
circumstances. In addition, missense mutations in theN-terminal domain of eme1in causes 
its mislocalization either to the cytoplasm or to the nucleoplasm (Ellis et al., 1999). Apart 
from being the major components of the nuclear lamina, lamins also f01m intranuclear 
structures as well as transnuclear tube-like structures (B1idges et al., 1993; Moir et al., 
1994; Fricker et al., 1997) in nonnal cells. 
Although cardiac and skeletal muscle are the only tissues affected in EDMD, the 
pattern of expression and cell distribution of emetin and lamins is the same in all tissues. 
The importance of that is that the diagnosis of the syndrome at present depends on mutation 
analysis. Diagnosing the condition therefore could be achieved by looking at altered 
expression of emerin or lamins in any kind of tissue, both affected and non-affected. 
Cardiac and skeletal muscle is difficult to be isolated. The most common technique used 
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cunently for the diagnosis of muscular dystrophies in muscle biopsy. Muscle biopsy is a 
surgical procedure in which one or more small pieces of muscle tissue are removed for 
microscopic or biochemical analysis. The procedure is considered minor surgery and is 
usually performed under local anaesthetic. lt involves 2-3 inch incision, which is then 
closed with stitches and may feel sore for a few days. Blood and skin are altemative 
sources of cells that could be used in diagnostic tests. Fibroblasts can be isolated by skin 
biopsy, a minor procedure without serious complications, much easier and more convenient 
for the patient; no stitches, no scaning, no pain. Lymphoblasts are even easier to isolate. 
Obtaining a blood sample is rapid and easy and gives much of the same information as 
muscle and skin cells. 
A simple test for diagnosing the condition therefore would be detecting the absence 
or presence of proteins and their distribution in the cell, in fibroblasts and lymphoblasts, 
using immunocytochemistry. This technique may be applied to suspected EDMD patients, 
especially sporadic, and also suspected caniers as simple and convenient. 
In the first two sets of experiments we investigated the endogenous and exogenous 
distribution of emerin and lamins in lymphoblasts and fibroblasts, by using antibodies 
against these proteins and GFP-, DsRed-tagged fusion proteins (GFP-emerin, GFP-lamin 
A, and DsRed-lamin C). Lymphoblasts were used in these experiments as, since they are 
easy to be isolated, a sample for every patient in Europe is available. However, fibroblasts 
are more representative and easier to be used for transfections. The experiments were 
performed in order to assess whether or not and the extend to which lymphoblasts and 
fibroblasts would be appropriate for use in diagnostic tests. 
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Materials &Methods 
Kmmunocytochemistry of LCLs 
Cell lines and Cell culture 
The lymphoblastoid cell lines from EDMD patients used in these experiments were 
obtained from Or Manfred Wehnert, University of Greifswald, Germany. They were grown 
in 50ml flasks in 10ml RPMI1640 medium (Gibco BRL) supplemented with 10% fetal calf 
serum (FCS, Sigma), 2mM L-Glutamine (Gibco BRL), 1 OOmM BME non-essential amino 
acid solution (Gibco BRL), and two antibiotics, lOU/ml penicillin and lOO~tg/ml 
streptomycin (Gibco BRL). Cell cultures were maintained in an incubator in humidified 
atmosphere with 5% C02 at 3rc, and the medium was replaced every three days. 
Eighteen cell lines from EDMD patients and two controls were examined in total. 
Out of the eighteen EDMD cell lines, two were of patients with lamin A/C gene mutations 
(AD-1, AD-2), six ofpatients with emerin gene mutations (X-1, X-2, X-3, X-4, X-5, X-6), 
and ten ofpatients screened for lamin 81, LAP213 and other proteins (S-1, S-2, S-3, S-4, S-
5, S-6, S-7, S-8, S-9, S-10). The mutations of these cell lines are detailed in Table 3. The 
two cell lines used as controls were cells of a Birkitts lymphoma cell line that does not 
express laminA, and nonnallymphoblastoid cells (control LCL). 
Antibodies 
The following primary monoclonal or polyclonal antibodies were used in these 
experiments: (i) RaLC against lamin Cat a dilution of 1:100, (ii) Jol2 against lamin A/C 
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Table 3. Lymphoblastoid cell lines and mutations 
Patient Mutation 
AD-EDMD 
AD-1 Exon 9, TGG>TCG;W520S 
AD-2 Exon 9, ACG>AAG;T528K 
X-linked EDMD 
X-1 delggcttagcaacagcgcagtgtc, nt -19 to -40 
of the emerin gene promoter 
X-2 del AG, nt 620-621 frameshift, stop after aa 
90 
X-3 Del TCT AC, nt 631-635 frameshift, stop 
after aa 90 
X-4 ins A, nt 895; frameshift, stop after aa 126 
X-5 nt 1713, C->T, codon 219, CAG->TAG, 
stop at codon 219 
X-6 Ins TGGGC, NT 1713, stop at codon 238, 
(Klauck et al., 1995) 
Patient Inheritance 
Sporadic EDMD 
S-1 EMD (two brothers) 
S-2 EMD (two brothers) 
S-3 ADEMD 
S-4 EMD sporadic 
S-5 EMD sporadic 
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S-6 EMD sporadic 
S-7 EMD (two brothers) 
S-8 EMD sporadic 
S-9 EMD sporadic 
S-10 EMD sporadic 
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used undiluted, (iii) GaiB1 against lamin 81 at a dilution of 1:100, (iv) LN43 specific for 
lamin 82 at a dilution of 1: I 0, and (v) NCL-emerin antibody at a dilution of 1:50. All 
primary antibodies used in this study are listed in Table 4. 
All the secondary antibodies used were obtained commercially from Jackson 
Immunoresearch, West Grove, P.A., and include : (i) TRITC-conjugated goat anti-rabbit 
IgG, (ii) TRITC-conjugated donkey anti-mouse IgG, and (iii) TRITC-conjugated donkey 
anti-goat IgG. All were used at a dilution of 1:50. 
Dilutions for both primary and secondary antibodies were done in blocking buffer 
(PBS containing 1% newbom calf serum). 
Immunofluorescence Microscopy 
For immunofluorescence, lymphoblasts were grown in 25ml flasks and in 1 Oml 
medium, until clamps of cells were visible (!:,rrowth rate varied amongst cell lines). They 
were then centrifuged at l OOOrpm for 5min and resuspended in 3ml medium. Cells were 
transferred on coverslips by cytospi1ming at 300rpm and at low acceleration for 5min, in a 
cytospin III (Shandon). 1 0 coverslips for each cell line were prepared, two for each of the 
primary antibodies, and 0.250ml of cell suspension were loaded in each cytofunnel. Once 
on coverslips, cells were fixed in pre-chilled methanol/acetone (1:1, v/v) for 10 minutes at 
4°C and washed three times in PBS. Before primary antibody addition, coverslips were 
washed with blocking buffer for 30 seconds. Antibody incubation time was 1 hr at room 
temperature for both primary and secondary antibodies, followed by three 15min washes 
with blocking buffer after the primary antibody addition and three 15min washes with PBS 
after the secondary antibody addition. Coverslips were mounted face down in Mowiol 
(Calbiochem) containing 1 ~tg/ml DAPI ( 4', 6-diamidin-2-phenylinolol-dihydrochloride) 
and 1 ~g/ml DAB CO (1 ,4-diazabicyclol [2.2.2]octane ). 
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'fable 4. Types of primary antibodies used 
Antibody Protein target Antibody type Dilution Source 
Ral C Lamin C Rabbit-polyclonal 1:100 V enables et al., 2001 
Jol2 Lamin A/C Mouse-monoclonal Undiluted Dyer et al., 1999 
Gal Bl Lamin Bl Goat-polyclonal 1: lOO Santa Cruz 
LN43 Lamin B2 Mouse-monoclonal 1:100 Dyer et al., 1999 
NCL-emerin Emerin Mouse-monoclonal 1:50 NovaCastra 
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Immunofluorescence samples were viewed with a Zeiss Axiovert 1 0 microscope 
equipped for epifluorescence using a p1an-APOCHROMAT 63x/1, 40 oil inm1ersion lens. 
Images were captured with a 12-bit CCD camera using IPLab Scientific Imaging Software 
(Scanalytis). 
Cell counting was conducted manually. More specifically, microscopic fields were 
randomly selected from each slide and vvere first viewed with the DAPI filter. All healthy 
looking single nuclei were counted, while clusters of cells with overlapping nuclei were not 
included in the scoring. The filter was then switched to Rhodamine and the cellular 
distribution of lamins and emerin in those nuclei was recorded as rim, cytoplasm, 
agb11·egates, and absent. 100 cells were counted from each of the two slides prepared per 
primary antibody, thus, 200 cells were counted in total. 
Immunocytochemistry of fibroblasts 
Cell lines and Cell culture 
Skin fibroblasts from EDMD patients were supplied by Professor Irena 
Housmanowa, Neurology Centre, Warsaw. They were grown in DMEM medium (Gibco 
BRL) supplemented with 10% fetal calf serum (Sigma), 1 OU/ml penicillin and IOO)lg/ml 
streptomycin (Gibco BRL), in 90mm petri dishes. Cell cultures were maintained in an 
incubator at a humidified atmosphere, with 5% C02 at 37°C and the cells were passaged at 
confluence for maintenance. 
Five fibroblastic cell lines were examined in total (four from patients and one 
control) after being transfected with pEGFP-LA, pEGFP-Emerin and DSRed1-LC 
constructs. The EDMD cell lines were from: an emerin null patient (X-EDMD1), that 
39 
Table 5. Fibroblastic cell lines and mutations 
Patient Mutation Emerin expression Lamin A/C expression 
X-EDMDl 386 del C -ve +ve 
X-EDMD2 AlllG -ve +ve 
X-EDMD Canier 386 del C -ve and +ve +ve 
AD-EDMD C1357T +ve +ve 
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patient's mother who is a manifested carrier (X-EDMD Carrier), a patient with an eme1in 
gene mutation (X-EDMD2), and an autosomal dominant EDMD patient (AD-EDMD). 
Details of the mutations of the cell lines examined are shown in Table 5. 
Plasmid Construction 
Green Fluorescent Protein (GFP) Fusion: To make pEGFP-LA, the pEGFP vector 
(Clontech Laboratories, Inc.) was cut with EcoRI and BamHI restriction enzymes and was 
thus linearized. Lamin A gene was cut out from pEGM-LA plasmid with the same 
enzymes, EcoRI and BamHI, and was subcloned in the linear pEGFP to construct pEGFP-
LA fusion protein. pEGFP-emerin was constructed previously (Vaughan et al., 2001). 
Red Fluorescent Protein (DsRed) Fusion: To make DsRedl-LC fusion protein, lamin C 
gene was amplified from a pET7-LC plasmid usmg the 
CTGAGAA TTCAA TGGAGACCCCGTCC-3' (forward primer) 
pnmers 
and 
5'-
5'-
TATATAGGTACCGCGGCGGCTACCACT-3' (reverse primer), ordered ti·om MWG-
Biotech AG. The primers were designed so as to contain an EcoRI restriction site and a 
Kpni restriction site in the f01ward and reverse primer respectively. The PCR product was 
digested with EcoRI and Kpni restriction enzymes. The DsRed 1 plasmid (Clontech 
Laboratories, Inc.) was also cut with the same enzymes. The two linear DNAs, lamin C and 
DsRed, were then ligated through their cut ends to construct DsRed 1-LC. 
Transfections and Microscopy 
Fibroblasts were transfected using a multiporator for eukaryotic cells (Eppendorf 
AG, Cambridge). For transfection, cells were harvested by trypsinization at 70-80% 
con fluency and centrifuged at 1 OOOrpm for 10 min at room temperature. They were then 
resuspended in DMEM containing 0.5% FCS and their number was determined. Cells were 
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centrifuged agam under the same conditions as before, and were resuspended in 
hypoosmolar electroporation buffer at a concentration of 1 06cells/ml. Plasmid DNA at a 
final concentration of 1 Opg/ml was added to the cell suspension, and 400pl of this mixture 
was transferred into the electroporation cuvette (2nm1 gap width aluminum cuvette). 
Electroporation conditions were as follows: mode: eukaryotes, voltage: 400V, time: 
1 OO~tsec, no of pulses: 1. After the pulse was delivered, the cell suspension was allowed to 
stand in the cuvette for 1 Omin at room temperature before being transferred to a 45mm 
culture dish containing 3ml medium and coverslips. The dish was kept in an incubator with 
5% C02, at Jrc. 36hrs after transfection, the coverslips were removed from the dishes, 
were washed with PBS and were fixed with methanol/acetone (1: 1, v/v) for 1 Omin at 4°C. 
They were then washed with PBS again, mounted on slides and observed under a 
microscope as described previously. 
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Results 
llmmunocytochemistry of LCLs 
The normal cellular distribution of lamin proteins and emerin is repeatedly shown 
by a number of studies to be afiected in muscle cells taken from patients with EDMD. Here 
we investigated the distribution of endogenous lamin A, C, B I, B2 and emerin in 
lymphoblasts (LCLs) of patients with X-linked, autosomal dominant and sporadic EDMD 
using immunofluorescence microscopy. The results obtained were compared with those 
collected from two lymphoblastoid cell lines used as controls. 
Lamin and emerin distribution in LCLs of patients with autosomal dominant EDMD. 
Immunofluorescence on LCLs taken from two AD-EDMD patients stained with 
antibodies against lamin A, C, B I, B2 and emerin, gave consistent results for both cell lines 
examined. Table 6 summarizes the immunofluorescence data collected from these two 
patients. 
From Table 6 and Figure 2 it can be seen that in these cell lines, lamin C was 
localized in the nuclear rim and in structures inside the nucleus giving a very bright 
staining. Lamins A, B I and B2 were mainly found in the nuclear rim. In a significant 
proportion of cells however cytoplasmic staining was also observed with these antibodies 
showing translocation of these proteins from the rim to the cytoplasm. The same holds for 
emerin as well. Emerin was shown to be localized in the nuclear rim in most cells but 
cytoplasmic staining was also observed in some of the cells scored. In both cell lines and 
with all antibodies' staining only a few cells remained unstained while no cells or just a 
few in the case of lamin A in AD-I and lamin C in AD-2 patient, showed aggregates of the 
protein. 
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Table 6. Lymphoblast staining of patients with AD-EDMD. 
(The numbers in the table show the number of nuclei with the particular staining pattem out of the total 200 
counted per antibody) 
STAINING 
Patient: RIM CYTOPLASM AGGREGATES ABSENT 
AD-1 Bright Dull 
Lamin C 117 64 6 0 l3 
Lamin A/C 64 73 43 10 10 
Lamin B1 93 28 78 0 1 
Lamin B2 88 59 36 0 17 
Emerin 63 111 21 0 5 
STAINING 
Patient: RIM CYTOPLASM AGGREGATES ABSENT 
AD-2 Bright Dull 
Lamin C 142 41 7 3 7 
Lamin A/C 140 22 36 0 2 
Lamin B1 20 100 45 0 35 
Lamin B2 145 22 24 0 9 
Emerin 59 99 42 0 0 
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Fig.2. The distribution of lam in C, lam in A/C, lam in B 1, lam in 82 and emerin 
in lymphoblastoid cel l lines of AD-EDMD. The distribution of DNA was detected 
with DAPI (panels A, D, G, J, M). TI1e distribution of lam in C, lam in A/C, lam in 
B I, lam in 82, and emerin, is shown in black and white micrographs in panels B, 
E, 1-l, K, and N respectively. Two colour merged images in which DAPI is shown in 
blue and the protein stained in red are shown in panels C, F, 1, L, 0 . 
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Lamin and emerin distribution in LCLs of patients with X-/inked EDMD. 
Immunofluorescence data collected from the five X-EDMD patients' cell lines is 
summarized in Table 7 and displayed in Figure 3. In all cell lines of this group of patients 
emerin staining was as expected absent, with the exception of X-1 patient. X-1 was known 
to have quantitatively less emerin present in muscle cells compared to normal individuals. 
Emerin staining in this patient's LCLs was visible in the nuclear rim as well as in structures 
inside the nucleus, but the staining was very dull. In addition, some cells appeared to have 
cytoplasmic staining of emerin as well. Lamin C was shown to be slightly affected in all 
five cell lines exanlined. Staining in this case was seen only in the rim and in intemal 
structures and not in the cytoplasm. However, in a small proportion of cells lamin C 
staining was absent. Finally, in all cell lines cytoplasmic translocation was observed for at 
least one or more lamins without however any evident pattem. More specifically, in 
patients X-1 and X-4, lamin A, lanlin B 1, and lamin B2 was translocated to the cytoplasm 
in a small but significant propm1ion of cells scored. In patients X-2, X-3, and X-5, laminA 
and lamin B 1 was seen in the cytoplasm in some cells, while there was no cytoplasnlic 
staining for lamin B2 in these patients. Finally, patient X-6 showed translocation to the 
cytoplasm only in the case of lam in B 1. All other lamins in this patient (lamin A, C, and 
B2) were clearly and only seen at the nuclear rim. 
Lamin and emerin distribution in LCLs of EDMD patients screened for lamin BJ, 
LAP2beta and other proteins. 
Data collected from the staining of the cell lines of the sporadic EDMD patients is 
shown in Table 8 and in Figure 4. Results in this group of patients varied significantly 
amongst the cell lines examined. No general pattern of change of distribution could 
therefore be seen. Interestingly however, in four out of the ten cell lines examined, there 
was either a dull staining of emerin throughout the whole nucleus (S-1, S-2), or no staining 
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Table 7. Lymphoblast staining of patients with X-linked EDMD 
(The numbers in the table show the number of nuclei with the particular staining pattern out of the total 200 
counted per antibody) 
STAINING 
Patient : RIM CYTOPLASM AGGREGATES ABSENT 
X-1 Bright Dull 
Lamin C 83 111 0 0 6 
Lamin A/C 92 88 11 0 9 
Lamin Bl 20 120 50 0 10 
Lamin B2 40 145 11 0 4 
Emerin 10 160 25 0 5 
STAINING 
Patient: RIM CYTOPLASM AGGREGATES ABSENT 
X-2 Bright Dull 
Lamin C 132 58 4 0 6 
Lamin A/C 157 22 15 3 3 
Lamin Bl 36 154 5 0 5 
Lamin B2 85 102 0 8 5 
Emerin 0 0 0 0 200 
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STAINING 
Patient: RIM CYTOPLASM AGGREGATES ABSENT 
X-3 Bright Dull 
Lamin C 114 71 3 0 12 
LaminNC 106 71 14 0 9 
Lamin B1 23 155 15 0 7 
Lamin B2 42 150 5 0 3 
Emerin 0 0 0 0 200 
STAINING 
Patient : RIM CYTOPLASM AGGREGATES ABSENT 
X-4 Bright Dull 
Lamin C 121 61 0 2 16 
Lamin A/C 118 45 16 4 17 
Lamin B1 91 80 11 0 18 
Lamin B2 140 45 15 0 0 
Emerin 0 0 0 0 200 
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STAINING 
Patient : RIM CYTOPLASM AGGREGATES ABSENT 
X-5 Bright Dull 
Lamin C 150 42 2 0 6 
Lamin A/C 143 43 10 2 2 
Lam in 81 47 140 7 0 6 
Lamin82 65 128 0 2 5 
Emerin 0 0 0 0 200 
STAINING 
Patient: RIM CYTOPLASM AGGREGATES ABSENT 
X-6 Bright Dull 
Lamin C 100 70 0 0 30 
Lamin A/C 109 79 0 0 12 
Lamin 81 20 127 33 0 20 
Lamin 82 32 163 0 0 5 
Emerin 0 0 0 0 200 
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Fig.3. The distribution of lamin C, lamin A/C, lamin 81 , lamin 82 and emerin in 
lymphoblastoid cell lines of X-EDMD patients. The distribution of DNA was detected 
with DAPI (panels A, D, G, J, M). The distribution of lam in C, lam in A/C, lam in 8 I, 
lamin 82, and emerin, is shown in black and white micrographs in panels 8, E, H, K, 
and N respectively. Two colour merged images in which DAPI is shown in blue and the 
protein stained in red are shown in panels C, F, I, L, 0 . 
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Table 8. Lymphoblast staining of patients with sporadic EDMD 
(The numbers in the table show the number of nuclei with the particular staining pattem out of the tota1200 
counted per antibody) 
STAINING 
Patient: RIM CYTOPLASM AGGREGATES ABSENT 
S-1 B1ight Dull 
Lamin C 80 84 8 4 24 
Lamin A/C 64 76 48 5 7 
Lamin Bl 34 84 52 0 30 
Lamin B2 75 54 61 3 7 
Emerin 8 4 0 0 188 
STAINING 
Patient : RIM CYTOPLASM AGGREGATES ABSENT 
S-2 Bright Dull 
Lamin C 51 71 0 0 78 
Lamin A/C 92 87 3 0 18 
Lamin B 1 10 100 70 0 20 
Lamin B2 110 50 30 0 10 
Emerin 0 10 15 0 175 
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STAINING 
Patient: RIM CYTOPLASM AGGREGATES ABSENT 
S-3 Bright Dull 
Lamin C 107 66 0 0 27 
Lamin A/C 102 67 3 3 25 
Lamin B1 48 90 54 0 8 
Lamin B2 63 68 61 3 5 
Emerin 52 80 65 0 3 
STAINING 
Patient: RIM CYTOPLASM AGGREGATES ABSENT 
S-4 Bright Dull 
Lamin C 110 79 0 0 1 l 
Lamin A/C 102 87 3 0 8 
Lamin B1 80 62 54 0 4 
Lamin B2 91 56 46 0 7 
Emerin 94 83 21 0 2 
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STAINING 
Patient : RIM CYTOPLASM AGGREGATES ABSENT 
S-5 Bright Dull 
Lamin C 68 96 0 0 36 
Lamin A/C 62 115 0 0 23 
Lamin B1 10 160 0 0 30 
Lamin B2 32 150 0 0 18 
Emerin 40 155 0 0 5 
STAINING 
Patient : RIM CYTOPLASM AGGREGATES ABSENT 
S-6 Bright Dull 
Lamin C 107 80 0 6 7 
Lamin A/C 86 90 2 6 16 
Lamin B1 15 160 20 0 5 
Lamin B2 27 148 15 0 10 
Emerin All cells stained pink 
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STAINING 
Patient : RJM CYTOPLASM AGGREGATES ABSENT 
S-7 Bright Dull 
Lamin C lOO 90 0 0 10 
Lamin A/C 105 80 6 0 9 
Lamin B1 81 98 18 0 3 
Lamin B2 39 120 31 0 10 
Emerin 70 102 24 0 4 
STAINING 
Patient: RIM CYTOPLASM AGGREGATES ABSENT 
S-8 Bright Dull 
Lamin C 77 99 3 0 21 
Lamin A/C 106 70 17 0 7 
Lamin Bl 20 137 40 0 3 
Lamin B2 57 116 22 0 5 
Emerin 10 173 10 0 7 
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STAINING 
Patient : RIM CYTOPLASM AGGREGATES ABSENT 
S-9 Bright Dull 
Lamin C 109 52 8 5 26 
Lamin A/C 77 74 26 9 14 
Lam in B 1 65 78 28 0 29 
Lamin B2 137 35 23 2 3 
Emerin 36 120 17 1 26 
STAINING 
Patient: RIM CYTOPLASM AGGREGATES ABSENT 
S-10 Bright Dull 
Lamin C 145 35 2 2 16 
Lamin A/C 141 40 2 2 15 
Lamin Bl 18 118 6 0 58 
Lamin B2 92 88 4 0 16 
Emerin All cells stained pink 
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Fig.4. The distribution of lam in C, lam in A/C, lam in 8 I, lam in 82 and emerin in 
lymphoblastoid cell lines of sporadic EDMD patients The distribution of DNA was 
detected with DAPI (panels A, D, G, J, M). The distribution of lam in C, lamin A/C, 
lam in 8 l, lam in 82, and emerin, is shown in black and white micrographs in panels 8, 
E, H, K, and N respectively. Two colour merged images in which DAPI is shown in 
blue and the protein stained in red are shown in panels C, F, I, L, 0. (Images taken 
from S-1 patient.) 
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at all (S-6, S-10). Generally, in all cell lines, all lamins' staining was shown to be affected 
either by partial translocation to the cytoplasm or/and by absence of staining or dull 
staining. More specifically, in many cell lines there was no lamin C staining in a relatively 
high proportion of cells while interestingly, this protein was the only one that was almost 
never seen in the cytoplasm in any of the cell lines examined. Lamin A and lamin B 1 on 
the other hand were seen both in the cytoplasm and/or were absent in a prop011ion of cells 
in the majority of cell lines. Lamin B2, was found to be translocated to the cytoplasm in a 
proportion of cells in all cell lines. 
Lam in and emerin distribution in LCLs of control cells. 
The inummofluorescence results of the two cell lines used as controls are shown in 
Table 9 and in Figure 5. Burk:itts lymphoma cell line which is deficient in laminA showed 
very weak staining for both laminA and lamin C. With both antibodies' staining, the nuclei 
of the cells appeared homogenously stained under the microscope with no apparent rim 
staining. In contrast, in control LCL cell line, staining of both lamin A and C was in the 
nuclear rim and in structures inside the nucleus as expected. Lamins B 1 and B2 as well as 
emerin were mostly localized in the rim and in structures inside the nucleus in 
both cell lines. However, a proportion of cells (higher in Burkitts lymphoma than in 
control LCL) stained with antibodies directed against these proteins also showed 
cytoplasmic staining. 
The pictures of LCLs' staining with antibodies shown in the figures were taken 
from some of the cell lines examined and are representatives, since the staining of all the 
other cell lines was similar. 
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Table 9. Lymphoblast staining of control cells 
(The numbers in the table show the number of nuclei with the particular staining pattem out of the total200 
counted per antibody) 
STAINING 
Control: RIM CYTOPLASM AGGREGATES ABSENT 
Burkitts Bright Dull 
lymphoma 
Lamin C Very dull staining 
Lamin A/C Very dull staining 
Lamin Bl lOO 66 27 0 7 
Lamin B2 85 79 32 0 4 
Emerin 90 78 24 0 8 
STAINING 
Control: RIM CYTOPLASM AGGREGATES ABSENT 
Control Bright Dull 
LCL 
Lamin C 156 44 0 0 0 
LaminA/C 147 51 2 0 0 
Lamin Bl 121 54 10 0 15 
Lamin B2 93 97 7 0 3 
Emerin 75 103 15 0 7 
58 
A B c 
-· 
D oj E F 
e 
G H I 
• • 
J ... .-r K ~ L •• -;.. 
• ··=-
• .~ , 
M N 0 
., .. ~. s•·J 
Fig.S. The distribution of lamin C, lam in A/C, lam in B I, lam in B2, and emerin in control 
LCL. The distribution of DNA was detected with DAPl (panels A, D, J, M). The 
distribution of lamin C, lamin A/C, lamin B 1, lamin B2, and emerin, is shown in black and 
white micrographs in panels B, E, H, K, and N, respectively. Two colour merged images 
in which DAPl is shown in blue and the protein stained in red are shown in panels C, F, l, 
L, O. 
hnmunocytochemistry of fibroblasts 
Construction of DsRed 1-Lamin C 
Lamin C was amplified by PCR and the product resolved on agarose gel along with 
positive and negative controls for the PCR reaction (Fig.6i). The band was cut, purified and 
subcloned into the DsRedl vector. To verify that the cloning procedure was successful 
diagnostic cuts were perfonned with EcoRI and Kpnl restriction enzymes. The cut DNA 
the linearized vector, and lamin C PCR product were all run on an agarose gel (Fig.6ii) . 
. The start and end parts of the sequence of the construct is shown in Figure 7. 
Constructs of lamin A fused to GFP, emerin fused to GFP and lamin C fused to 
DsRed were created and transiently expressed in fibroblasts of EDMD patients and of 
healthy individuals. To investigate the cellular localization of the transiently expressed 
constructs, inununofluorescence microscopy was performed using fibroblasts fixed 36hrs 
after transfection. 
Distribution of DsRed-LaminC in fibroblasts of AD-EDMD, and X-linked EDMD patients 
[n patient X-EDMDl who is an emerin null patient, the GFP-emerin construct was 
distributed in the NE in the majority of transfected fibroblasts. However, in some 
fibroblasts the construct was also found translocated outside the nucleus, dispersed into the 
cytoplasm. In Fig.8, panels A-C, a fibroblast transfected with GFP-emerin is shown. 
Emerin in that fibroblast is localized in the NE with no cytoplasmic staining seen. The 
DsRed-LC construct was observed to be distributed in the NE and, in addition, in patch-like 
structures inside the nucleus. The distribution of the construct in the NE is illustrated in 
Fig.8, panels 0-F. The patch-like structures are not visible here. Finally, the GFP-LA 
construct was clearly seen only in the NE and no cell was recorded in which GFP-LA was 
located elsewhere. The NE distribution of GFP-LA is shown in Fig.8, panels G-I. 
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Fig.6. Gels illustrating the production of lamin C from the PCR reaction and the diagnostic 
cutting of the DsRed-LC construct 
(i) 
1 2 3 4 5 6 
(ii) 
1 2 3 4 5 6 7 
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Lane 1 : Ladder 
Lane 2: Negative control 
Lane 3, 4, 5: DsRed-LC 
Lane 6: Positive control 
Lane 1, 2, 3, 6, 7: DsRed-LC 
construct cut with EcoRI 
and Kpni 
Lane 4 : Lamin C, product of 
PCR reaction 
Lane 5 : Linear DsRed 
Fig. 7. The nucleotide sequence of DsRed-LC construct 
Sequence from primer C 
ATACNCCTCGTGGAGCAGTACGAGCGCACCGAGGGCCGCCACCACCTGTTCCTGCTCAG 
ATCTCGAGCTCAAGCTTCGAATTCAATGGAGACCCCGTCCCAGCGGCGCGCCACCCGCA 
GCGGGGCGCAGGCCAGCTCCACTCCGCTGTCGCCCACCCGCATCACCCGGCTGCAGGAG 
AAGGAGGACCTGCAGGAGCTCAATGATCGCTTGGCGGTCTACATCGACCGTGTGCGCTC 
GCTGGAAACGGAGAACGCAGGGCTGCGCCTTCGCATCACCGAGTCTGAAGAGGTGGTCA 
GCCGCGAGGTGTCCGGCATCAAGGCCGCCTACGAGGCCGAGCTCGGGGATGCCCGCAA 
GACCCTTGACTCAGTAGCCAAGGAGCGCGCCCGCCTGCAGCTGGAGCTGAGCAAAGTGC 
GTGAGGAGTTTAAGGAGCTGAAAGCGCGCAATACCAAGAAGGAGGGTGACCTGATAGCT 
GCTCAGGCTCGGCTGAAGGACCTGGAGGCTCTGCTGAACTCCAANGAGGCCGCACTGAG 
CACTGNTCTTAGTGAGAAGCGCACGCTGGANGGGCGAGCTGCATGATTTGCGGGGCCCA 
GGTGGNCAANCTTTGAGGCANCCCTANGTGAAGGGCCAAAAAGCAAC 
Sequence from primer N 
AAGNCGTCCAGGCGAAGGGCAGGGGGCCGCCCTTGGTCACCTTCAGCTTCACGGTGTTG 
TGGCCCTCGTAGGGGCGGCCCTCGCCCTCGCCCTCGATCTCGAACTCGTGGCCGTTCAC 
GGTGCCCTCCATGCGCACCTTGAAGCGCATGAACTCCTTGATGACGTTCTTGGAGGAGC 
GCACCATGGTGGCGACCGGTAGCGCTAGCGGATCTGACGGTTCACTAAACCAGCTCTGC 
TTATATAGACCTCCCACCGTACACGCCTACCGCCCATTTGCGTCAATGGGGCGGAGTTGT 
TACGACATTTTGGAAAGTCCCGTTGATTTTGGTGCCAAAACAAACTCCCATTGACGTCAA 
TGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTAC 
TGCCAAAACCGCATCACCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTA 
GGAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATT 
GACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAG 
TTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCTATTGGNGTTACTATGGG 
AACATACNTCATTATTGACNTNAATG 
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Fig.8. The distribution of GFP- emerin (A-C), DsRed-lamin C (D-F) and GFP-
Iamin A (G-1) in X-EDMD1 patient's fibroblasts. Panels A, D and G show DAPI 
staining. Panels B, E, and H show staining with GFP-emerin, DsRed-lamin C 
and GFP-Iamin A respectively and panels C, F, and I are merged images. 
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Fig.9. The distribution of GFP- emerin (A-C), DsRed-lamin C (D-F) and GFP-
Iamin A (G-1) in X-EDMD patient's fibroblasts. Panels A, D and G show DAPI 
staining. Panels B, E, and H show staining with GFP-emerin, DsRed-lamin C and 
GFP-Iamin A respectively and panels C, F, and I are merged images. 
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The same pattem of distribution was also observed with all constructs in the case of 
X-EOMO Canier, who is emerin null only in half of the cells, as shown in Fig.9. The 
GFP-emerin construct illustrated in panels A-C is shown here to be partly distributed in the 
NE and partly dispersed into the cytoplasm. The DsRed-LC construct in panels 0-F is an 
example of a fibroblast manifesting patch-like structures inside the nucleus with no NE 
distribution. In panels G-1, GFP-LA construct is again seen in the NE. 
In patient X-EOMD2 who is emerin deficient, GFP-eme1in construct was 
mainly found in the cytoplasm, while in some cells it could also be seen in the NE. A 
fibroblast with cytoplasmic distribution of GFP-emerin as well as some NE localization of 
the construct is illustrated in Fig. I 0, panels A-C. In this patient, DsRed-LC was found both 
in structures (patches) inside the nucleus and in the NE as seen in panels D-F. Finally, 
GFP-LA was again only seen in the NE, panels G-I 
In AO-EDMO, a patient with lamin A/C gene mutation, GFP-emerin construct was 
seen both in the NE and dispersed into the cytoplasm. In Fig. II, panels A-C, a fibroblast 
with mainly cytoplasmic localization of GFP-emerin is shown. The DsRed-LC construct 
was found dishibuted in the NE and in patches inside the nucleus, as seen in panels 0-F. 
On the other hand however, AD-EDMD fibroblasts transfected with GFP-LA showed NE 
distribution in only very few cells, which was in addition dull. A representative cell 
transfected with the GFP-LA construct is shown in panes! G-I. 
Nonnal fibroblasts were transfected with all the created constructs and the results 
obtained were compared to those of the EDMO cell lines. The GFP-LA construct was 
found in the NE and the DsRed-LC one was seen both in the NE and inside the nucleus 
forming aggregates. The GFP-emerin construct on the other hand was seen in the NE as 
well as in the cytoplasm. Results of nonnal fibroblasts n·ansfected with the three constructs 
are not shown here. 
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Fig.10. The distribution of GFP- emerin (A-C) , DsRed-lamin C (D-F) and GFP-
Iamin A (G-1) in X-EDMD2 patient's fibroblasts. Panels A, D and G show DAPI 
staining . Panels 8 , E, and H show staining with GFP-emerin, DsRed-lamin C 
and GFP-Iamin A respectively and panels C, F, and I are merged images. 
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Fig.11. The distribution of GFP- emerin (A-C) , DsRed-lamin C (0-F) and GFP-
Iamin A (G-1) constructs in AD-EDMD patient's fibroblasts. Panels A, D and G 
show DAPI staining. Panels B, E, and H show staining with GFP-emerin, 
DsRed-lamin C and GFP-Iamin A respectively and panels C, F, and I are 
merged images. 
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Chapter 2. The nuclear lamina and cell cycle effects in EDMD cells 
Introduction 
In recent years it has become evident that a number of human genetic diseases arise 
as a result of mutations in proteins that are involved in the establishment of nuclear 
structure and architecture (Wilson, 2000; Hutchison et al., 2001 ). This indicates that nuclear 
architecture is closely related to and is very important for nuclear function. 
Both emetin and lamins as mentioned in the general introduction are implicated 
directly or indirectly in the organization and maintenance of the nuclear structure, as well 
as in nuclear function. Mutated emerin gives tise to EDMD implying a possible function in 
transcription regulation (Morris and Manila!, 1999). In addition, lamins have been 
repeatedly repotied to be involved in DNA replication (Ellis et al., 1997; Spann et al., 1997; 
Moir et al., 2000). The above findings suggest that these proteins may be further involved 
in the regulation of the cell cycle and the progression of the cells through it. 
The measurement of the DNA content of cells was one of the first maJor 
applications of flow cytometry. The DNA content of a cell can provide a great deal of 
infonnation on the distribution of cells at the different phases of the cell cycle, and 
consequently on the effect of a number of factors including mutated or absent proteins on 
the cell cycle. 
In this set of experiments we investigated the effects of mutated or absent emerin 
and mutated lamin A/C on cell cycle progression in fibroblasts from EDMD patients using 
flow cytometry. Fibroblasts from a nonnal individual were also used for comparison. Since 
emerin's and lamins' role-function in the cell imply that they also affect indirectly the 
progression of the cells through the cell cycle, it was expected that the distribution of cells 
around the cycle would be altered in fibroblasts from patients. Normal tibroblasts display 
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regulated cell growth and division in culh1re and they respond to high density in culture by 
entering the GO phase of the cycle. In the mutant cell lines examined, two possible types of 
abnormalities were expected; an abnormal progression through S-phase (longer S-phase) 
and an abnormal response to growth signals (G2 accumulation instead of GO at 
confluency). 
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Materials and Methods 
Cell lines and Cell culture 
The same cell lines of skin fibroblasts from EDMD patients and the same culture 
conditions were used in this study as described in chapter 1. Nonnal fibroblasts were also 
used in these experiments. Five fibroblastic cell lines were examined in total (four from 
patients and one from a healthy individual-control). More specifically, the EDMD cell lines 
were from: an emerin null patient (X-EDMD1), that patient's mother who is a manifested 
can·ier (X-EDMD Carrier), a patient with an emerin gene mutation (X-EDMD2), and an 
autosomal dominant EDMD patient (AD-EDMD). Details of the mutations of the cell lines 
examined are shown in Table 5. 
Skin fibroblasts from EDMD patients were supplied by Professor Irena 
Housmakowa, Neurology Centre, Warsaw. They were grown in DMEM medium (Gibco 
BRL) supplemented with 10% fetal calf serum (Sigma), 1 OU/ml penicillin and 1 OO~tg/ml 
streptomycin (Gibco BRL), in 90nun petri dishes. Cell cultures were maintained in an 
incubator at a humidified atmosphere, with 5% C02 at 3rc and the cells were passaged at 
confluence for maintenance. 
DNA staining and FACS analysis 
For F ACS analysis cells were grown 111 90mm petri dishes, allowed to reach 
confluency, and subcultured at a dilution of 1:3. Fibroblasts were analyzed on clay 3, 5, and 
I 0 after passage. The DNA of the fibroblasts was stained using propidium iodide. Cells 
from each of the five cell lines were harvested by trypsinization on day 3, 5 and 10 after 
subculturing and were collected by centrifugation at 1 OOOrpm for 5min. They were then 
resuspencled in lml PBS and centrifuged again at 2000rpm for 5nlin. After that, they were 
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resuspended in and 1ixed with 0.5ml pre-chilled 70% ethanol while vortexing. After being 
kept for 10 minutes at 4°C, the fixed cells were centrifuged at 2000rpm for 5min and 
washed twice in PBS. Finally, they were treated with 1001-tl ribonuclease (1 OO)lg/ml) for 
5min at room temperature and stained with 4001-d propidium iodide (501-tg/ml). Cell cycle 
analysis was perfom1ed in Coulter Epics XL F ACS analyzer. Flow cytometric data was 
acquired using System II software. 
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Results 
One of the characteristic features of emerin is its high serine residues content which 
can be phosphorylatecl/dephosphorylated by various kinases. Studies have shown that 
nom1al emerin can occur in four different phosphorylated forms, tluee of which seem to be 
associated with the cell cycle as discussed previously. In addition, nuclear lamins have also 
been speculated to be involved in cell cycle progression by playing a role in NE assembly 
and growth. To fmther investigate the involvement of emerin and lamins in cell cycle 
progression, we performed cell cycle analysis in fibroblasts of patients with different forms 
of EDMD using a F ACS analyzer. Representative data obtained from these experiments is 
shown in Fig.12- Fig.16. The fibroblasts were tested at passage 7, 8 ancl9. 
In Figure 12 the distribution of the control fibroblasts throughout the cell cycle at 
passage 7 is shown. The general pattem was two peaks, one very sharp at the GO-G 1 phase 
of the cycle and one much smaller and broader at G2 phase. The fraction of cells was the 
same at all passages and at different cell cycle phases for each day of analysis and was 
regarded as normal cell cycle distlibution. More specifically, on day 3 (Fig. 12a) 61.6% of 
the cells were in Gl, 15.9% were inS, and 6.33% were in G2/M (86.6% counted). On day 5 
(Fig. 12b), 63.2% of the cells were in G I, 9.27% were in S, and 6.31% were in G2/M 
(78.1% cells counted). Finally, on day 10 (Fig. 12c ), 66.5% of the cells were in G 1, 12% 
were in S, and 4.46% were in G2/M (88.3<X) cells counted). 
In Figure 13, data collected from X-EDMDl patient at passage 7 and on days 3, 5 
and 10, is illustrated. At passage 7, and on clay 5, the distribution of cells throughout the 
cell cycle was as in the control, although the GO-G 1 peak was broader in this case. 
Interestingly however, on clays 3 and I 0, the distribution varied quite a lot from that of the 
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JFig.12a. The distribution of cells throughout the cell cycle in the healthy individual on day 
3. The first panel shows the shape of the cells (granularity vs size). The second panel 
shows the distribution of the cells in Gl- (E), S- (F), and G2/M- (G) phase ofthe cycle. The 
number of cells counted and the percentage of the cells in each phase is shown in the table 
below the panels. 
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1Fig.12b. The distribution of cells throughout the cell cycle in the healthy individual on day 
5. The first panel shows the shape of the cells (granularity vs size). The second panel 
shows the distribution of the cells in G 1- (E), S- (F), and G2/M- (G) phase of the cycle. The 
number of cells counted and the percentage of the cells in each phase is shown in the table 
below the panels. 
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1Fig.12c. The distribution of cells throughout the cell cycle in the healthy individual on clay 
I 0. The first panel shows the shape of the cells (granularity vs size). The second panel 
shows the distribution of the cells in Gl- (E), S- (F), and G2/M- (G) phase ofthe cycle. The 
number of cells counted and the percentage of the cells in each phase is shown in the table 
below the panels. 
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Fig.13a. The distribution of cells throughout the cell cycle in X-EDMD 1 on day 3. The 
first panel shows the shape of the cells (granularity vs size). The second panel shows the 
distribution of the cells in G 1- (E), S- (F), and G2/M- (G) phase of the cycle. The number 
of cells counted and the percentage of the cells in each phase is shown in the table below 
the panels. 
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lFig.13b. The distribution of cells throughout the cell cycle in X-EDMDl on day 5. The 
first panel shows the shape of the cells (granularity vs size). The second panel shows the 
distribution of the cells in G 1- (E), S- (F), and 02/M- (G) phase of the cycle. The number 
of cells counted and the percentage of the cells in each phase is shown in the table below 
the panels. 
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JFig.13c. The distribution of cells throughout the cell cycle in X-EDMD 1 on day 10. The 
first panel shows the shape of the cells (granularity vs size). The second panel shows the 
distribution of the cells in G 1- (E), S- (F), and G2/M- (G) phase of the cycle. The number 
of cells counted and the percentage of the cells in each phase is shown in the table below 
the panels. 
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control with less cells found at G 1 and more at S-phase compared to the control. Moreover, 
on day 10, a peak was observed at S-G2 phase of the cycle, which was quite similar to the 
GO-G 1 one. Finally, on day 10 there were more cells at G2 phase than on day 3 and 5 and 
compared to the control as well. The granularity and the size of fibroblasts remained the 
same on all three days. The percentage of cells in each phase of the cycle for each day of 
analysis is shown in Figure 13. On day 3 (Fig. 13a) 50.6(% of the cells were in G 1, 26.4% 
were inS, and 7.19% were in G2/M (85.1% cells counted). On day 5 (Fig. 13b), 67% ofthe 
cells were in G1, 12.9% were inS, and 2.37% were in G2/M (83.9% cell counted). Finally, 
on day 10 (Fig. 13c), 26.2% of the cells were in G1, 41.9% were inS, and 19.3% were in 
G2/M (87. 7% cells counted). The distribution of cells at passage 8 was as at passage 7. At 
passage 9, the cells appeared to be larger and more granular than at passage 7. Except from 
the broader than nom1ally GO-G 1 peak observed again at passage 9, the cell cycle 
distribution here was similar to that at passage 7 on day 3. On day 5 however, a second 
peak was again observed in S-G2 phase which persisted on day 10 as well. Data from 
passage 8 and passage 9 is not shown here. 
The distribution of fibroblasts throughout the cell cycle in X-EDMD Carrier seemed 
to be quite similar to that of X-EDMD1 patient on day 3 at passages 7, 8 and 9 with the 
broad GO-G 1 peak appearing here again. More specifically, on clay 3 cells seemed to 
progress slower through S-phase compared to the control. On clay 5 however and even 
more on clay 1 0, the percentage of cells in S-phase decreased while that of G 1-phase 
increased, resembling the control. The morphology of the cells was the same as in X-
EDMD1 patient. Data collected from this patient at passage 7 is shown in Figure 14. On 
clay 3 (Fig. 14a) 42.9% of the cells were in G1, 30.7% were inS, and 7.39% were in G2/M 
(88.9% cells counted). On day 5 (Fig. 14b), 64.2% ofthe cells were in Gl, 19SYo were in 
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Fig.14a. The distribution of cells throughout the cell cycle in X-EDMD CatTier on day 3. 
The first panel shows the shape of the cells (granularity vs size). The second panel shows 
the distribution of the cells in G 1- (E), S- (F), and G2/M- (G) phase of the cycle. The 
number of cells counted and the percentage of the cells in each phase is shown in the table 
below the panels. 
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JF'ig.l4b. The distribution of cells throughout the cell cycle in X-EDMD Canier on day 5. 
The first panel shows the shape of the cells (granularity vs size). The second panel shows 
the distribution of the cells in G 1- (E), S- (F), and G2/M- (G) phase of the cycle. The 
number of cells counted and the percentage of the cells in each phase is shown in the table 
below the panels. 
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Fig.14c. The distribution of cells throughout the cell cycle in X-EDMD Carrier on day 10. 
The first panel shows the shape of the cells (granularity vs size). The second panel shows 
the dist1ibution of the cells in G 1- (E), S- (F), and G2/M- (G) phase of the cycle. The 
number of cells counted and the percentage of the cells in each phase is shown in the table 
below the panels. 
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S, and 3.76% were in G2/M (88.5% cells counted). Finally, on day 10 (Fig. I4c), 63.I% of 
the cells were in G I, I4.3% were inS, and 2.65% were in G2/M (85.8% cells counted). 
In X-EDMD2 patient (Fig. IS) the pattem of distribution was normal at all passages 
with the GO-G I peak being sharper here and the whole pattern being very similar to that of 
the control fibroblasts. Data shown in Figure 15 is from passage 7. On day 3 (Fig. !Sa) 
57.3% of the cells were in G1, I6.3% were inS, and 3.08% were in G2/M (93.7% cells 
counted). On day 5 (Fig. I5b), 53.5% of the cells were in G I, I 0.8% were in S, and 2.3I% 
were in G2/M (75.5% cells counted). Finally, on day 10 (Fig. I5c), 59.5% ofthe cells were 
in G 1, 18.1% were in S, and 2.4% were in G2/M (84.4% cells counted). 
Data collected from AD-EDMD patient from passages 7, 8 and 9 showed that the 
distribution of these cells was different from that of the control with the broad peak in Go-
G 1 phase being present here again. Fibroblasts of this patient seemed to progress slower 
tlu·ough S-phase as in X-EDMDI and X-EDMD Canier. Furthermore, accumulation at 
confluence was observed at G 1-phase as in the X-EDMD Carrier. Representative data from 
this patient at passage 7 is shown in Figure 16. On day 3 (Fig. 16a) 55.5% of the cells were 
in GI, 21.9% were in S, and 4.03% were in G2/M (90% cells counted). On day 5 (Fig. 
I6b), 47.6% of the cells were in GI, 21.6% were inS, and 4.81% were in G2/M (95.3% 
cells counted). Finally, on day 10 (Fig. I6c ), 63.1% of the cells were in G 1, 25.4% were in 
S, and 5.66% were in G2/M (92.4% cells counted). Cell morphology was the same as in the 
other patients. 
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Fig.15a. The distribution of cells throughout the cell cycle in X-EDMD2 on day 3. The first 
panel shows the shape of the cells (granularity vs size). The second panel shows the 
distribution of the cells in G 1- (E), S- (F), and G2/M - (G) phase of the cycle. The number 
of cells counted and the percentage of the cells in each phase is shown in the table below 
the panels. 
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1Fig.15b. The distribution of cells throughout the cell cycle in X-EDMD2 on day 5. The 
first panel shows the shape of the cells (granularity vs size). The second panel shows the 
distribution of the cells in G 1- (E), S- (F), and G2/M- (G) phase of the cycle. The number 
of cells counted and the percentage of the cells in each phase is shown in the table below 
the panels. 
) \ G .. ~ r---1 ........ 
1824 
ss FLJ 
Slat.s: Nonn.alizcd, Listgating: Di&abkd 
!list RgJ;ion ID ~ COU!!t M!!.ll MnY Pkl'o!l> !Y!!!Y l'tCD! Pf£YX PPCYY 
1 A A 1S.S 2947 391.8 466.S 304.0 288.0 14 35.96 36.16 
lli.st R~ion ID ~ CoJ!m Mnl!: MdX PlcPooX ~n! H!'£Y M in MM 
4 E E S3.S IS76 410.0 409.8 402.0 54 2.82 388.0 432.0 
p F 10.8 318 543.8 463.0 448.0 18 O.IS 444.0 780.0 
G G 2.31 68 814.8 811.2 797.0 4 0.09 792.0 862.0 
85 
Fig.15c. The distribution of cells throughout the cell cycle in X-EDMD2 on day 10. The 
nrst panel shows the shape of the cells (granularity vs size). The second panel shows the 
distribution of the cells in G 1- (E), S- (F), and G2/M- (G) phase of the cycle. The number 
of cells counted and the percentage of the cells in each phase is shown in the table below 
the panels. 
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1Fig.16a. The distribution of cells throughout the cell cycle in AD-EDMD on day 3. The 
first panel shows the shape of the cells (granularity vs size). The second panel shows the 
distribution of the cells in G 1- (E), S- (F), and G2/M- (G) phase of the cycle. The number 
of cells counted and the percentage of the cells in each phase is shown in the table below 
the panels. 
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Fig.16b. The distribution of cells throughout the cell cycle in AD-EDMD on day 5. The 
first panel shows the shape of the cells (granularity vs size). The second panel shows the 
distribution of the cells in G 1- (E), S- (F), and 02/M- (G) phase of the cycle. The number 
of cells counted and the percentage of the cells in each phase is shown in the table below 
the panels. 
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Fig.16c. The distribution of cells throughout the cell cycle in AD-EDMD on day I 0. The 
first panel shows the shape of the cells (granularity vs size). The second panel shows the 
distribution of the cells in G 1- (E), S- (F), and G2/M- (G) phase of the cycle. The number 
of cells counted and the percentage of the cells in each phase is shown in the table below 
the panels. 
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Discussion 
!mmunocytochemistry of lLCLs 
The nom1al cellular distribution of lamins and emerin has been shown to be affected 
in muscle cells taken from patients with EDMD. From the immunofluorescence microscopy 
results of lymphoblasts taken from EDMD patients and healthy individuals, (Table 6, 7, 8, 
and 9), it is possible that the same holds for lymphoblastoid cells as well. However, only 
one control LCL was available for the experiments conducted, Burkitts lymphoma being an 
established cell line with clear differences in lamin A expression. This, and the variability 
of the EDMD LCLs makes it difficult to evaluate the significance of the differences for 
EDMD, without a large number of control LCLs. 
More specifically, in the two AD-EDMD patients' LCLs, the mutation on the lamin 
NC gene is found on exon 9, and affects the expression of lamin A protein, whereas lamin 
C production does not appear to be atTected by the mutation. Lamin A as seen from Table 
6, was translocated to the cytoplasm in both patients, in a significant number of cells 
scored. From experiments conducted previously, it has been shown that the distribution of 
lamin B 1 and B2 is not affected by absence/deficiency of lamin A, implying that A- and B-
type lamins' possible interactions are not essential for the assembly and maintenance of the 
nuclear lamina. From this finding it can also be assumed that lamin A is not involved 
directly in the localization of B-type lamins. Comparing the results of the two AD-EDMD 
cell lines however with that of control LCL cell line, it can be seen that in these 
experiments B-type lamins were affected by the translocation of lamin A. A higher number 
of cells showing cytoplasmic staining for B-type lamins was seen in the two AD-EDMD 
cell lines examined compared to control LCL cell line. The distribution of lamin C was 
clearly seen to be only slightly atTected by the mutation of laminA as shown in Table 5 and 
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when compared to Burkitts lymphoma and control LCL cell lines. However, as seen m 
Table 9, in the case of Burkitts lymphoma cell line lamin C was absent (no staining 
occuned) or was found in very few cells, giving a very dull staining of nuclei. The above 
indicate a possible interaction between laminA and lamin C, which may be involved in the 
localization of lamin C. Although absence of lamin C was unexpected, it has been 
previously speculated (Hutchison et al., 2001) that laminA stabilizes lamin C. Mutations in 
lamin A/C gene therefore resulting in absence/deficiency of lamin A, could lead to the 
dissociation of lamin C with the nucleus and consequently translocation of lamin C from 
the NE to the cytoplasm. Furthermore, absence of lamin C from cells could be the result of 
degradation following disassociation of the protein with the nucleus. It should be noted at 
this point that the results collected for the two AD-EDMD patients do not strongly support 
the above speculations since in those cases there is no great change in lamin C distribution. 
However, it can be assumed that the mutations in these two patients are not located in sites 
critical for the lamin A-lamin C interaction. 
Recently, it has been shown that lamin A binds directly to emenn m vitro 
(Clements et al., 2000). Taking this into account, the results summarized in Table 6 were as 
expected. Emerin in both EDMD cell lines was localized in the cytoplasm in a diffused 
form in a high proportion of cells compared to control LCL, and being very similar to 
Burkitts lymphoma, while dull staining on the nuclear envelope has also been observed. 
This is possibly due to emerin not been anchored to the nuclear envelope because of the 
mutation in lamin A/C gene. Redistribution of emerin was expected because previous 
studies indicate that lamin A/C anchors emerin at the NE (Sullivan et al., 1999). Finally, 
emerin has also been shown to interact with B-type lamins. Diffusion of lamins in the 
cytoplasm in a propm1ion of cells seen in both AD-EDMD cell lines as well as Burkitts 
lymphoma, could therefore be explained as misanchoring of B-type lamin to the NE. 
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From Table 7 in which the results of the X-linked EDMD patients are summarized, 
emerin staining was only seen in patient X-1. Mutations in all other patients resulted in no 
emerin expression at all and thus no staining occurred. In these patients, lamin C was seen 
to be slightly affected. This indicates that there is possible interaction between emerin and 
lamin C and is thus in agreement with the prediction made by Yaughan and coworkers 
(Vaughan et al., 2001). In all patients' cell lines, some or alllamins (laminA, 81, and 82) 
were seen to be affected. Although loss of laminA and B-type lamins to the cytoplasm was 
unexpected, it may again suggest that in these cells emerin influence lamins association 
with the nucleus. However, no general pattern can be seen and thus no firm conclusion can 
be drawn. 
From the data collected from sporadic EDMD patients (Table 8), no general pattern 
of distribution of the lamins could again be identified and therefore no conclusion can be 
drawn from these results either. However, it is interesting to note that in this case in four 
out of the ten patients examined in total, emerin was not localized in the nuclear envelope 
nor was it diffused in the cytoplasm. In S-1 and S-2 patients, the majority of the cells were 
not stained with the emerin antibody, whereas in S-6 and S-1 0 patients, emerin appeared to 
be diffused inside the nucleus. This result suggests two possible explanations; Degradation 
of emerin due to instability of assembly with the NE, and/or deficient transport of the 
protein through the endoplasmic reticulum. The results obtained here are very interesting 
and require further investigation of the four cell lines. 
Immunocytochemistry of fibroblasts 
In order to investigate the distribution of emerin, lamin A and lamin C in fibroblasts 
of EDMD patients, four cell lines of patients' fibroblasts and one of a healthy individual 
were transfected with GFP-emerin, GFP-LA and DsRed-LC constructs. As was clearly 
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shown in these experiments and can be seen from Figure 8, 9 10, and 11, the distribution of 
transfected lamin A, lamin C and emerin, does not appear to be affected in the cell lines 
examined. Data collected from the normal fibroblasts, is the same as that collected from the 
EDMD cell lines. In all five cell lines the GFP-emerin construct was seen both in the 
nuclear rim and diffused in the cytoplasm. GFP-LA, and DsRed-LC on the other hand were 
both found in the nuclear rim while DsRed-LC was also seen in patches inside the nucleus. 
Overall, using this approach no abnonnalities in lamin assembly pathways were observed 
(Ostlund et al., 2001 ). Apart from all the above however, when interpreting the results, it 
should be taken into account that the transfection et1iciency was very low. Only 5% of the 
total population of cells was transfected. More experiments therefore on the same cell lines 
have to be conducted optimizing the conditions of electroporation so that higher 
transformation efticiencies are reached. 
While some evidence of structural abnormality was observed in LCLs, none was 
seen in fibroblasts. Perhaps the effect if any on LCLs and even more on tibroblasts, is weak 
and would only be observed in muscle cells. Therefore ideally the experiments should be 
repeated in skeletal muscle. The cunent data does not lend strong suppm1 to the hypothesis 
that EDMD arises from weakness ofthe lamina (Hutchison et al., 2001). 
Overall, from the inummocytochemistry experiments on lymphoblasts conducted, 
one can conclude that although some differences are suggested in EDMD, much more study 
is required before the possibility of using such differences for diagnosis can be considered. 
Furthennore, transfection of fibroblasts did not show up any differences between EDMD 
and control cells that might be useful in diagnosis. Finally, more experiments have to be 
designed and performed in order to investigate the causes of muscular dystrophy in 
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sporadic EDMD patients, and to explain the absence/deficiency of emerin observed in the 
lymphoblasts ofthe four out of the ten patients examined in this study. 
The nuclear lamina and cell cycle effects in EDMD cells 
Nuclear lamins have been speculated to be involved in the progression of the cell 
through the cell cycle by playing a central role in the assembly of the nuclear envelope and 
growth. Emerin has also been found to exist in the cell in four phosphorylated fonns, out of 
which three have been shown to be associated with the cell cycle. According thus to the 
above and if these assumptions are true, it would be expected that mutations in the genes 
encoding lamins and emerin would have an effect of some kind on the progression of the 
cells through the different phases of the cycle. F ACS analysis was thus performed on 
fibroblastic cell lines taken from patients with AD- and X-linked EDMD to investigate 
whether or not there is an effect on the cell cycle. 
From the results section and figures 12-16, it can be clearly seen that there is a 
significant difference in the distribution of cells around the cycle amongst the five different 
cell lines. The four patients' cell lines had one feature in conunon in their distribution 
which was different from control cells. The peak at the GO-G I phase of the cycle was much 
broader in these cell lines compared to the control, and although it was less broad in the 
case of X-EDMD2 patient, the difference was still evident. The same peak was very sharp 
for the control cell line. One feature that was very interesting and appeared in the 
distribution pattems of both X-EDMDl and X-EDMD2 cell lines, was the peak that was 
seen at S-G2 phase of the cycle after 5 days in culture. These two patients had both 
mutations in the emerin gene. That peak was not however observed in X-EDMD CmTier 
and AD-EDMD cell lines, bearing mutations in emerin (carrier) and lamin A genes 
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-respectively. The broader than normal peak seen in all EDMD cell lines could be explained 
in ten11s of cell cycle block or apoptosis. Cells may be accumulating at GO phase of the 
cycle either because the mutation has been spotted and is lethal for the cells so they are 
going through apoptosis or because they are blocked by checking mechanisms. The second 
peak observed in S-G2 phase is clearly a cycle arrest. From the percentage of the cells in 
each phase of the cycle, it can be suggested that with the exception of X-EDMD2, emerin 
and lamin mutations cause cells to progress through S-phase slower than normal due to 
checking mechanisms/cycle an·est. That becomes more evident in the case of X-EDMDI 
patient in which cells at confluence accumulate in S/G2- phase instead of G 1 as in the 
control cells. 
The above assumption of cell cycle arrest, can be explained in terms of the Rb 
protein. The most severe lamina abnormalities have been observed in X-EDMD patients. 
Moreover, lamins are shown to be Rb binding partners. Taking these two points into 
account, perhaps absence/mutation of lamin C or emerin, or both, causes mis-regulation of 
Rb and consequently cell cycle arrest. 
At this point it should be noted that control and patient fibroblasts were compared 
by F ACS with a manifesting catTier. The carrier will have a mixture of emerin expressing 
and emerin null cells, the majority being emerin expressing since manifesting. The carrier's 
cell cycle distribution of the cells should therefore be somewhere between the patient's and 
the control's but closer to the patient's one. Although this is a good internal control for the 
technique, it does not fit the expected pattern. 
Although the differences between the five cell lines examined here may be genuine, 
the factor of variable penetrance has to be considered as well. In addition, when hypotheses 
about emerin effects on cell division are evaluated, the fact that people with no emerin at all 
(X-EDMD patients) grow to normal adult stature at non11al rates must be considered. 
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Clearly, neither lack of emenn nor the pathogenic lamin A/C mutations have any 
significant effects on cell growth and cell number at the level of the whole organism. 
In order to investigate further the effects of lamins and emerin mutations on the 
cells' cycle, more work needs to be conducted. Fm1her immunocytochemical and 
biochemical experiments need to be perfonned and the work canied out here should be 
repeated using more cell lines from EDMD patients. 
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